ALK and non-small cell lung carcinoma: Preclinical research demonstrated that combining ceritinib (an ALK inhibitor) with a PD-L1 inhibitor suppressed PD-L1 expression and enhanced lymphocyte activity in ALK-rearranged NSCLC [120].